15 Recruiting Focal Segmental Glomerulosclerosis Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Top Recruiting Focal Segmental Glomerulosclerosis Studies
RECRUITING Phase2 💊 Investigational Drug / Biologic
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔ 🟢 Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
📍 Loma Linda University Children's Hospital — Loma Linda, California
View Study & Checklist ➔ 🟢 Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
📍 Loma Linda University Children's Hospital — Loma Linda, California
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
📍 Cedars-Sinai Medical Center — Los Angeles, California
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
📍 Investigator Site #2 — Chula Vista, California
View Study & Checklist ➔ 🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
📍 University of Michigan — Ann Arbor, Michigan
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
AMPK-activation by Metformin in FSGS: AMP-FSGS
📍 Yale New Haven Hospital — New Haven, Connecticut
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
📍 Investigational Site Number : 8400007 — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
📍 BIDMC — Boston, Massachusetts
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
📍 Alabama Kidney Research — Alabaster, Alabama
View Study & Checklist ➔